Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower CVD compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Heart failure knowledge Analysis 1.1 · adults with heart failure
1 finding from 1 review
Heart failure self‐efficacy Analysis 1.2 · adults with heart failure
1 finding from 1 review
Heart failure self‐care Analysis 1.3 · adults with heart failure
It is very uncertain whether mHealth education intervention changes heart failure self‐care Analysis 1.3 compared with usual care (very low certainty).
1 finding from 1 review
Adverse events · adults with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life Analysis 1.4 · adults with heart failure
1 finding from 1 review
Heart failure hospitalisation (RR) · adults with heart failure
mHealth education intervention showed no clear difference in heart failure‐related hospitalisations Analysis 1.5 compared with usual care (low certainty).
1 finding from 1 review